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ABSTRACT 
FK228 (Romidepsin) and suberoylanilide hydroxamic acid (SAHA, Vorinostat) are FDA-
approved histone deacetylase inhibitors (HDACi) for Cutaneous T-cell Lymphoma (CTCL), 
including the leukemic subtype Sézary Syndrome (SS). This study investigates RAD23B and 
STAT3 gene perturbations in a large cohort of primary Sézary cells and the effect of FK228 
treatment on tyrosine phosphorylation of STAT3 (pYSTAT3) and RAD23B expression. We 
report RAD23B copy number variation in 10% (12/119; p ≤ 0.01) of SS patients, associated 
with reduced mRNA expression (p = 0.04). RAD23B knockdown in a CTCL cell line led to a 
reduction in FK228-induced apoptosis. HDACi treatment significantly reduced pYSTAT3 in 
primary Sézary cells and was partially mediated by RAD23B. A distinct pattern of RAD23B-
pYSTAT3 co-expression in primary Sézary cells was detected. Critically, Sézary cells 
harbouring the common STAT3 Y640F variant were less sensitive to FK228-induced 
apoptosis and exogenous expression of STAT3 Y640F and D661Y conferred partial 
resistance to STAT3 transcriptional inhibition by FK228 (p ≤ 0.0024). These findings suggest 
that RAD23B and STAT3 gene perturbations could reduce sensitivity to HDACi in SS 
patients.  
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INTRODUCTION 
Sézary Syndrome (SS) is the leukemic variant of Cutaneous T-cell Lymphoma (CTCL) and is 
associated with poor prognosis (Kim et al. 2005) and is often refractory to treatment. The 
histone deacetylase inhibitors (HDACi) FK228 (Romidepsin) and suberoylanilide 
hydroxamic acid (SAHA, Vorinostat) are FDA-approved for relapsed or refractory CTCL and 
a response is seen in 30% of patients (Whittaker et al. 2010). The biological pathways by 
which HDACi exert their clinical efficacy are incompletely understood and there is a clinical 
need to predict response.  
Increased expression of RAD23B (also known as HR23B) has been reported as a sensitivity 
determinant for SAHA response and proposed as a biomarker for tumour sensitivity to 
HDACi therapy (Fotheringham et al. 2009; Khan et al. 2010). RAD23B was first purified in a 
nucleotide excision repair (NER) complex and was named due to its homology to the 
Saccharomyces cerevisiae RAD23 gene (Masutani et al. 1994). Another RAD23 homologue, 
RAD23A, also exists in humans. However, RAD23A and RAD23B have been proposed to 
adopt distinct roles during HDACi response based on apoptosis studies (Fotheringham et al. 
2009). RAD23B is a dual function ubiquitin receptor thought to play a role in proteasomal 
targeting and transcriptional control (Chen and Madura 2002; Kim et al. 2004; Wade and 
Auble 2010; Wilkinson et al. 2001) alongside its role in NER (Masutani et al. 1994; Mueller 
and Smerdon 1996; Watkins et al. 1993). RAD23B mediates tumour sensitivity to HDACi 
via its proteasomal role (Khan et al. 2010). RAD23B single nucleotide variation (SNV) or 
copy number variation (CNV) have not yet been reported in CTCL. 
Increased levels of active, tyrosine-phosphorylated STAT3 (pYSTAT3) in tumours has been 
associated with resistance to SAHA (Fantin et al. 2008; Lu et al. 2014). STAT3 is a 
transcription factor which, upon cytokine-dependent phosphorylation and activation by JAK 
kinases, mediates T-cell proliferation, differentiation and growth (Rawlings et al. 2015). 
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STAT3 is vital for healthy immune function but is commonly dysregulated in cancer and is 
frequently perturbed in CTCL (Kiel et al. 2015; Park et al. 2017; da Silva Almeida et al. 
2015; Ungewickell et al. 2015; Woollard et al. 2016). Somatic STAT3 Src Homology 2 
(SH2)-domain Y640F and D661Y mutations have been shown to confer gain-of-function 
signalling in multiple cancer types (Couronné et al. 2013; Koskela et al. 2012; Pilati et al. 
2011; Walker et al. 2016).  
Activated STAT3 is regulated by protein phosphatase activity (Kim et al. 2018) and by 
ubiquitin-dependent proteasomal degradation, suggesting a possible link between STAT3 and 
RAD23B (Thurman et al. 2012; Wei et al. 2012).  
Here, we show that RAD23B CNV in primary Sézary cells is associated with reduced 
RAD23B mRNA expression. Furthermore, in vitro, RAD23B knockdown partially mediates 
the HDACi-induced reduction of pYSTAT3 and confers partial resistance to FK228-induced 
apoptosis. We also show that FK228 significantly reduces pYSTAT3 expression in primary 
Sézary cells and demonstrate a distinct profile of RAD23B-STAT3 co-expression. 
Importantly, our study shows that the common gain-of-function STAT3 Y640F mutation 
confers partial resistance to FK228. 
RESULTS 
High frequency RAD23B CNV and reduced RAD23B mRNA expression in primary 
Sézary cells  
Analysis of chromosome 9 SNP array data identified large-scale copy number (CN) loss in 
3/16 SS patients and large-scale CN gain in one patient (Figure 1a). Specifically, CN loss of 
the region on the 9q31.2 band harbouring the RAD23B gene was identified in 2/16 patients. 
Taqman qPCR confirmed the loss of RAD23B in all samples in which a CNV was identified, 
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and additionally identified a sample with RAD23B CN gain, where large-scale gain adjacent 
to this region was identified by SNP array (Figure 1b). Overall, Sézary cells from 20% (3/15) 
of patients harboured RAD23B CNV (p ≤ 0.001) relative to none of 92 healthy control 
samples. A further 104 SS samples in addition to 15 of the original cohort (n = 119; Figure 
1c) were analysed and RAD23B CNV was called in 10% (12/119) of patients (6 CN loss, 6 
CN gain, p ≤ 0.001).  
Gene expression qPCR demonstrated that the RAD23B mRNA level did not differ 
significantly in Sézary cells relative to healthy controls (Figure 1d). However, Sézary cells 
harbouring RAD23B CNV showed significantly reduced RAD23B mRNA expression 
compared with those with normal RAD23B CN (p = 0.04).  
FK228 downregulates pYSTAT3 and RAD23B expression  
Next, we investigated the effect of HDACi treatment on pYSTAT3, STAT3 and RAD23B 
protein co-expression and apoptosis by intracellular flow cytometry. TSA and FK228 
treatment of HUT-78 cells significantly reduced RAD23B, STAT3 and pYSTAT3 protein 
expression (p = 0.0001; Figure 2a) and induced apoptosis (Figure 2b).   
A distinct pattern of RAD23B-STAT3 co-expression was observed during HDACi treatment, 
whereby reduced STAT3 activity preceded loss of RAD23B expression (Figure 3a). 
Treatment with TSA or FK228 led to a substantial reduction in pYSTAT3; however, the 
majority of cells retained expression of RAD23B (Figure 3b). In apoptotic cells, the loss of 
pYSTAT3 was more pronounced and an increased proportion of dual negative cells was 
observed (Figure 3c). The RAD23BnegpYSTAT3+ population remained negligible under all 
conditions. 
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Downregulation of pYSTAT3 by FK228 and TSA is partially dependent on RAD23B  
To investigate the relationship between RAD23B and pYSTAT3 during HDACi response, 
siRNA-mediated RAD23B knockdown was established in HUT-78 cells (Figure 4a–b) and 
apoptosis and pYSTAT3 expression were analysed by flow cytometry (Figure 4c). In control 
(scrambled siRNA) transfected cells, TSA and FK228 induced apoptosis in 60% and 45% of 
cells, respectively. After RAD23B knockdown, the proportion of apoptotic cells was reduced 
compared with control cells, highlighting the role for RAD23B in HDACi-induced apoptosis. 
In the control cells, TSA and FK228 reduced pYSTAT3 expression by 80% and 50%, 
respectively, compared with untreated cells. However, after RAD23B knockdown, pYSTAT3 
was reduced by only 30% by TSA and 20% by FK228. These findings suggest a novel 
RAD23B-STAT3 relationship, whereby the absence of RAD23B reduces dephosphorylation 
of STAT3 in response to HDACi treatment. Immunoprecipitation of STAT3 from HUT-78 
cells indicates that a direct interaction between RAD23B and STAT3 may be responsible for 
this relationship (Supplementary figure S1).  
Primary Sézary cells show a distinct pattern of RAD23B-STAT3 co-expression and 
variable apoptotic responses after HDACi treatment  
In ex vivo primary Sézary cells from six SS patients, FK228 significantly reduced total 
STAT3 expression in all patient samples tested (p ≤ 0.04; Figure 5a) compared with CD4+ T-
cells from healthy controls. Increased pYSTAT3 expression was observed in three untreated 
primary Sézary samples compared with healthy controls (p = 0.001) but, consistent with data 
in HUT-78 cells, FK228 treatment significantly reduced pYSTAT3 in all Sézary and control 
cells (p ≤ 0.0001) (Figure 5b). 
RAD23B and pYSTAT3 co-expression was investigated in live primary Sézary cells. 
Interestingly, although high levels of pYSTAT3 were detected in untreated Sézary cells from 
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three patients, pYSTAT3 was detected in up to 38% cells in these patients (Figure 5c). 
Untreated, live Sézary cells were predominantly RAD23BhighpYSTAT3neg (62.4%) whilst 
25.8% of cells were RAD23BhighpYSTAT3+ compared with a value of 8.8% in healthy 
control cells (Figure 5d). Consistent with findings in HUT-78 cells, FK228 treatment led to 
an 18% reduction in the RAD23BhighpYSTAT3+ population, whilst there was a modest 
increase in the RAD23BhighpYSTAT3neg and RAD23BlowpYSTAT3neg populations. 
Furthermore, primary Sézary cells did not express pYSTAT3 in the absence of high RAD23B 
expression, and apoptotic Sézary cells expressed negligible levels of pYSTAT3 (Figure 5e). 
The effect of FK228 on induction of apoptosis was further investigated in primary Sézary 
cells. Two samples were excluded due to low cell viability in untreated cells. One sample 
(P18) exhibited similar sensitivity to FK228 compared to the healthy controls, whilst Sézary 
cells from two patients (P3 and P19) demonstrated increased sensitivity. Interestingly, Sézary 
cells from one patient (P17) demonstrated reduced sensitivity to FK228 compared with the 
other tumour and healthy samples (Figure 5f).  
The STAT3 Y640F mutation persists in multiple SS tumour compartments  
Genomic data for these patients were available to investigate the presence of RAD23B CNV 
and STAT3 gene perturbation. In these six samples, no RAD23B CNV was detected and 5/6 
samples were JAK/STAT3 wildtype. Interestingly, Sézary cells derived from P17 harboured 
the STAT3 Y640F variant, had high levels of pYSTAT3 (Figure 5b) and were partially 
resistant to FK228-induced apoptosis (Figure 5f). The STAT3 Y640F variant was identified in 
3/101 SS patients, including P17, previously reported by our group (Woollard et al. 2016). In 
our current study, we demonstrated the persistence of this A>T variant in serial clinical 
samples from multiple tumour compartments over time in P17.  Furthermore, transcription of 
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the variant allele was confirmed (Figure 6a). STAT3 Y640F was also detected in multiple, 
tumour compartments in two further patients (Supplementary figure S2).  
A comprehensive analysis of publicly available whole-exome sequencing data from mature 
T-cell malignancies identified STAT3 SNVs in 8.6% (40/466) of tumours (Jiang et al. 2015; 
Kataoka et al. 2015; Kiel et al. 2015; McKinney et al. 2017; Moffitt et al. 2017; da Silva 
Almeida et al. 2015). The STAT3 Y640F SH2-domain mutant, detected in 2.4% (11/466) of 
tumours, was the most frequently reported, whilst the STAT3 SH2-domain D661Y variant 
was detected in 1.9% (9/466) of tumours (Supplementary table S1). 
The STAT3 Y640F and D661Y variants confer partial resistance to FK228-mediated 
STAT3 transcriptional inhibition  
We performed functional analysis using an in vitro model to assess the impact of mutant 
STAT3 on STAT3 activity after FK228 treatment. By immunoblot, we demonstrated that the 
STAT3 Y640F and D661Y variants were constitutively phosphorylated in HEK293T cells 
(Supplementary figure S3). Reduction of STAT3 transcriptional activity after FK228 
treatment has been reported (Tiffon et al. 2011), therefore we tested the effect of FK228 
treatment on STAT3 luciferase reporter activity (Figure 6b). In untreated cells, the STAT3 
Y640F and D661Y variants conferred increased reporter activity compared with wildtype 
(WT) protein (p ≤ 0.0024). FK228 treatment reduced WT STAT3 reporter activity by 94% 
compared with untreated cells. In contrast, FK228 reduced STAT3 Y640F and D661Y 
reporter activity by only 40% or 55%, respectively, and therefore the SH2-domain mutants 
had significantly increased activity compared with WT after FK228 treatment (p ≤ 0.0001), 
suggesting partial resistance to HDACi-induced transcriptional inhibition. Thus this in vitro 
data is consistent with the reduction in FK228-induced apoptosis observed in primary Sézary 
cells harbouring the STAT3 Y640F variant. 
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DISCUSSION  
This study has shown that STAT3 tyrosine phosphorylation in primary Sézary cells is 
significantly reduced following FK228 treatment and that STAT3 gene mutations confer 
partial resistance to FK228. Furthermore, our data suggests that RAD23B and STAT3 may 
interact to modulate the response to FK228 in SS. We also identified a specific RAD23B 
CNV at the 9q31.2 locus in 10% of primary Sézary tumours.  
Chromosome 9 structural abnormalities have been reported in SS (Espinet et al. 2004; 
Salgado et al. 2010); however, to our knowledge there are no studies examining CNV at the 
RAD23B locus. Importantly we show that RAD23B CNV is associated with reduced RAD23B 
mRNA expression in primary Sézary cells and that RAD23B knockdown down-regulates 
FK228- and TSA-induced apoptosis in HUT-78 cells. This is consistent with previous 
findings that RAD23B knockdown in cell lines led to decreased apoptosis following SAHA 
treatment (Fotheringham et al. 2009; Khan et al. 2010). These data suggest that Sézary cells 
with RAD23B CNV and reduced RAD23B expression may be less sensitive to FK228 
therapy, although this could not be investigated due to a limited number of primary Sézary 
cells derived from patients with known RAD23B CNV.  
We and others have previously demonstrated constitutive activation of the STAT3 oncogene 
(Bromberg et al. 1999) in SS (McKenzie et al. 2012; Sommer et al. 2004), which has been 
linked to neoplastic transformation of CTCL (Sommer et al. 2004). Our data now 
demonstrate that FK228 treatment significantly reduces STAT3 transcriptional activity in 
vitro and confirms that STAT3 tyrosine phosphorylation in primary Sézary cells is 
significantly reduced following FK228 treatment. Our findings are consistent with studies 
showing that SAHA and FK228 reduce STAT3 activity in cell lines (Ierano et al. 2013; 
Tiffon et al. 2011). HDACi treatment has been shown to affect STAT3 cellular localisation 
(Duvic et al. 2007) and acetylation, which in turn mediates STAT3 activity (Ray et al. 2005; 
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Wang et al. 2005). FK228-dependent STAT3 inhibition is likely to contribute to its 
therapeutic effectiveness because STAT3 is an anti-apoptotic factor (Lu et al. 2014). This is 
supported by our observation of pYSTAT3 expression in live but not apoptotic primary 
Sézary cells following HDACi treatment. 
We have shown that the STAT3 Y640F mutation, reported in different mature T-cell 
malignancies (Jiang et al. 2015; Kataoka et al. 2015; Kiel et al. 2015; McKinney et al. 2017; 
Moffitt et al. 2017; da Silva Almeida et al. 2015), persists in multiple tissue compartments 
from three SS patients. Interestingly, we also observed in ex vivo primary Sézary cells that 
the STAT3 Y640F mutant was associated with high levels of constitutive pYSTAT3 and was 
resistant to FK228-induced apoptosis compared with other tumour samples that were STAT3 
wildtype. This finding may explain the previous reported association of increased pYSTAT3 
expression with reduced response to SAHA in CTCL (Fantin et al. 2008), although the role of 
STAT3 genotype in HDACi-resistance was not investigated. Our in vitro data demonstrated 
that STAT3 Y640F and D661Y, another common SH2 domain variant, both confer 
constitutive STAT3 phosphorylation and increased transcriptional activity, which is 
consistent with studies in other malignancies (Couronné et al. 2013; Koskela et al. 2012; 
Pilati et al. 2011). Critically, we have also demonstrated that STAT3 gain-of-function 
mutations mediate partial resistance to FK228 inhibition of STAT3 transcriptional activity 
and induction of apoptosis. Interestingly a recent report has identified the STAT3 Y640 
residue as a site of TYK2-dependent phosphorylation, which suppresses STAT3 
transcriptional activity (Mori et al. 2017). This was validated by demonstrating that the 
Y640F mutation led to inactivation of the normal inhibitory regulation of this residue, 
enabling constitutive activation of the mutant STAT3 protein. The demonstration that STAT3 
genotype influences primary tumour HDACi sensitivity could have significant clinical 
relevance in SS. 
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Our findings demonstrate that pYSTAT3 response to HDACi is partially dependent on 
RAD23B. Specifically, we identified a distinct pattern of RAD23B and STAT3 co-expression 
following HDACi treatment, whereby pYSTAT3 expression is not detected in cells with low 
RAD23B expression. These findings suggest a direct STAT3-RAD23B protein-protein 
interaction in CTCL cells, which is also supported by the detection of RAD23B-STAT3 
protein complexes by co-immunoprecipitation. Interestingly, both STAT3 and RAD23B have 
been shown to interact with HDAC6 (Cheng et al. 2014; Cheng et al. 2012; New et al. 2013). 
RAD23B mediates the degradation of ubiquitinylated proteins (Kim et al. 2004) and has been 
shown to contribute to SAHA responses (Khan et al. 2010). STAT3 is also regulated by 
ubiquitin-dependent protein degradation in T-cells (Qu et al. 2012; Tanaka et al. 2011) as 
well as through phosphatase-dependent degradation of pYSTAT3 (Kim et al. 2018). 
Therefore, a potential explanation for the partial FK228-resistance of the STAT3 Y640F 
variant could be that this negative TYK2-phosphorylation site is also linked to RAD23B 
mediated proteasomal degradation. Further work is now required to investigate the functional 
mechanism of the novel RAD23B-STAT3 interaction, and to determine if these findings 
relate to STAT3 tumour genotype. 
Quantitative analysis of pYSTAT3 expression in primary Sézary cells after FK228 treatment 
has to our knowledge not been previously reported. We have demonstrated frequent RAD23B 
and STAT3 gene perturbations in SS patients and have also identified a link between 
RAD23B expression, STAT3 genotype and HDACi response in Sézary cells.  A proposed 
model summarising the functional effect of HDACi on RAD23B and STAT3 in Sézary cells 
is shown in Supplementary figure S4. These findings suggest that STAT3 and RAD23B 
tumour genotype may influence the sensitivity to HDACi in SS patients.  
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MATERIALS AND METHODS 
Patients and cell lines 
All samples used in this study derived from patients who fulfilled the WHO-EORTC 
diagnostic criteria for SS and were classified at blood stage B2 (Swerdlow SH et al. 2017) 
with an identical clonal TCR rearrangement identified in lesional skin and peripheral blood. 
All patient and healthy control samples provided informed written consent and were obtained 
from our ethically approved research tissue bank (IRAS Project ID: 238203).  The rationale 
for patient sample selection is included in supplementary methods. HUT-78 and HEK293T 
cells were purchased from The European Collection of Authenticated Cell Cultures. 
Isolation of Sézary cells 
Peripheral blood CD4+-enriched Sézary cells were isolated using LymphoprepTM 
(STEMCELL Technologies, 07851) following incubation with RosetteSep TM Human CD4+ 
T Cell Enrichment Cocktail (STEMCELL Technologies, 15022). 
Cell culture 
The HUT-78 cell line is an HTLV-negative SS-derived line (Bunn and Foss 1996; 
Netchiporouk et al. 2017). HUT-78 cells (maintained between passage 2–20) and primary 
CD4+ T-cells were cultured in RPMI medium (Gibco, 11875085) supplemented with 10% 
Fetal Bovine Serum (FBS; ThermoFisher Scientific, 10500064), 100 U/mL penicillin and 100 
µg/mL streptomycin (Sigma, P4333). HEK293T cells (maintained between passage 2–25) 
were cultured in DMEM (Gibco, 61965026) supplemented with 10% FBS, penicillin and 
streptomycin. Cells were cultured at 37°C in the presence of 5% CO2 and 95% humidity and 
were routinely tested for Mycoplasma contamination using PCR (van Kuppeveld et al. 1994). 
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Cells were treated with DMSO vehicle control, 1 µM Trichostatin A (TSA Sigma, T1952) or 
1 µM FK228 (Romidepsin; Generon, HY-15149) for 20–24 hours in complete medium.   
Single Nucleotide Polymorphism (SNP) Array 
HumanOmni5Exome array (Illumina) of Sézary cell DNA from 16 SS patients was analysed 
using OncoSNP v1.4 after extraction of raw data (B allele frequencies and log R ratios) using 
Illumina Genome Studio software (Woollard et al. 2016). 
Copy number analysis 
Real-time PCR was performed on the ABI prism 7000 sequence detection system (Applied 
Biosystems). CN analysis was conducted using the Hs02323598_cn RAD23B probe/primer 
set and the TERT Ref CN and RNaseP Ref CN TaqMan probe/primer sets. Each DNA 
sample was analysed in quadruplet using the TaqMan Universal Mastermix II (ThermoFisher 
Scientific, 4440040) using the standard curve method. Patient samples were compared with a 
healthy control panel (Sigma HRC-1, 06041301).  
Gene expression analysis 
Total RNA was extracted from CD4+-enriched tumour samples using the RNeasy Plus Mini 
Kit (Qiagen, 74136). cDNA was synthesized using the High-capacity RNA-to-cDNATM kit 
(ThermoFisher Scientific, 4387406).  Gene expression was determined by Hs00234102_m1 
RAD23B and Hs01565700_g1 PPIA probe/primer sets using the TaqMan Fast Advanced 
Mastermix (ThermoFisher Scientific). Assays were performed in triplicate analysed by the 
∆Ct method.  
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Detection of apoptosis, RAD23B, pYSTAT3 and STAT3  
Cells were stained with Fixable Viability Stain (FVS 780; BD, 565388) and Annexin V-
Pacific BlueTM (BioLegend, 640918) following the manufacturer’s instructions. After fixation 
and permeabilization with 1% paraformaldehyde and 90% methanol, cells were stained with 
Alexa Fluor® (AF) 647 anti-STAT3 Phospo (Tyr705) antibody (BioLegend, 13A3-1), PE-
STAT3 antibody (BioLegend, 15H2B45) and RAD23B polyclonal Alexa Fluor® 488 
antibody (Bioss Antibodies, bs-15482R-A488). FLOW acquisition of 10,000 events was 
performed using a BD FACSCantoTM II. Thresholds were determined using fluorescence-
minus-one staining. Standardised machine settings were retained throughout the study. Data 
was analysed using Flowing Software 2 (Perttu Terho). ∆MFI was calculated by subtracting 
the median fluorescence intensity of the fluorescence-minus-one from the sample. SEM was 
calculated from the percentage coefficient of variance and event number. For single 
intracellular staining of pYSTAT3, cells were incubated with anti-Tyr705 pYSTAT3 
antibody (CST, #9145) before incubation with the fluorescently-labelled Alexa Fluor 555-
conjugated goat anti-mouse antibody, as described (McKenzie et al. 2012). The Annexin V-
PE apoptosis detection kit I (BD Pharmingen, 559763) was used for independent assessment 
of apoptosis. 
Immunoblotting  
For analysis of pYSTAT3 in HUT-78 cells, pYSTAT3 was stabilised by treatment with 100 
µM pervanadate (New England Biolabs, P0758) for two minutes prior to harvesting. For 
immunoblots, 15 µg of whole cell lysate were probed with primary antibodies: rabbit 
monoclonal pYSTAT3 (1:1000, Tyr705, D3A7; Cell Signalling Technologies [CST] #9145), 
mouse monoclonal STAT3 (1:1000, CST, 124H6, #9139), rabbit polyclonal RAD23B 
(1:1000, Bethyl Laboratories, A302-306A), mouse monoclonal RAD23B (1:1000, Santa 
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Cruz, sc-136052) and rabbit monoclonal GAPDH (1:2000, CST, #14C10). Duplicate blots 
were probed in parallel with pYSTAT3 and STAT3 antibodies before probing each blot with 
α-GAPDH. Signals were detected using horseradish peroxidase-conjugated anti-rabbit (Dako, 
P0448) or anti-mouse (Abcam, ab6789) antibodies.  
siRNA knockdown 
HUT-78 cells were electroporated using the Gene Pulser® II Electroporation System (Bio-
rad) at 240V and 975uF with 100 nM of RAD23B-specific (D-011759-04) or scrambled 
siRNA (D-001206-13-05; both Dharmacon) and cultured for 48 hours as described (Verma et 
al. 2010) . RAD23B depletion was confirmed by immunoblot and by PCR of cDNA using 
RAD23B-specific primers (5’-TGACCCCGAGGAGACGGTGA-‘3; reverse: 5’-
GCAGGTGTGGAAGTGGGGGC-‘3) and cyclophilin-specific primers as described 
(McKenzie et al. 2012).  
PCR and Sanger sequencing 
Regions harbouring SNVs in tumour-derived DNA or cDNA were amplified by PCR using 
AmpliTaq Gold DNA Polymerase (ThermoFisher Scientific, N8080241) prior to Sanger 
sequencing (Source Bioscience, Cambridge, UK). 
Cell transfection and Luciferase Reporter Assays  
HEK293T cells were transiently transfected with wildtype or mutant pCi-STAT3 constructs 
or pCi empty-vector control using poly(ethylenimine) (Sigma, 9002-98-6), as described 
(Longo et al. 2013). HEK293T cells were co-transfected with 1 µg of the STAT3-luciferase 
reporter plasmid (kindly provided by Prof. Uwe Vinkemeier, University of Nottingham) and 
0.5 ng Renilla pRLTK control plasmid (John et al. 1999). Dual Luciferase® Reporter Assays 
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(Promega, E1980) were performed in triplicate using an Orion II Microplate Luminometer 
(Berthold Detection Systems). Firefly luciferase activity was standardised to Renilla.  
Statistical analysis 
Statistical significance was assessed using a one-way ANOVA using GraphPad Prism 
Version 7, La Jolla, California, USA. 
Data availability statement 
Datasets related to this article can be found at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE80650, hosted at NCBI’s Gene 
Expression Omnibus Series accession number GSE80650  
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FIGURE LEGENDS 
 
Figure 1: RAD23B CNV in Sézary cells is associated with reduced RAD23B mRNA 
expression. (a) A heat map indicating SNP array-derived CN data across chromosome 9 for 
patients 1–16 (P1–16). (b) TaqMan qPCR to validate RAD23B CN using the standard curve 
method for P1–11 and P13–P16 relative to 92 healthy controls. RAD23B CN was not tested in 
P12 due to lack of sample availability.  (c) TaqMan qPCR to calculate RAD23B CN in 
peripheral blood mononuclear cell (PBMC) DNA from 119 SS patients and 92 healthy 
controls; solid and dashed lines represent the mean +/-3SD, indicating criteria for calling 
CNV (p ≤ 0.01). (d) Gene expression TaqMan qPCR for a subset of the patients from (c). 
Statistical significance was tested using a one-way ANOVA with multiple comparisons; * p < 
0.05. 
Figure 2: HDACi treatment reduces pYSTAT3 expression and induces apoptosis. HUT-
78 cells were treated with vehicle control, 1 µM TSA or 1 µM FK228 and stained with FVS, 
Annexin V-Pacific Blue, α-pYSTAT3-AF 647, α-STAT3-PE and α-RAD23B-AF 488, prior 
to flow cytometry analysis. (a) ∆MFI plotted with SEM. (b) HDACi-induced apoptosis. 
Annexin Vneg FVSneg = ‘live’, Annexin V+ FVSneg = ‘early apoptotic’ and AnV+ FVS+ = ‘late 
apoptotic’. Bars represent the percent of total cells. 10,000 events were collected for each 
experiment. (a) = representative data from two biological repeats; (b) = pooled data from two 
biological repeats. One-way ANOVA analysis with multiple comparisons was used to test the 
statistical significance relative to vehicle-treated, *** = p ≤ 0.0001; * = p < 0.05. 
Figure 3: A distinct pattern of pYSTAT3 and RAD23B co-expression in HUT-78 cells 
following HDACi treatment. HUT-78 cells were treated with vehicle control, 1 µM TSA or 
1 µM FK228 and stained with FVS 780, Annexin V-Pacific Blue, α-pYSTAT3-AF 647, α-
STAT3-PE and α-RAD23B-AF 488 prior to flow cytometry analysis. (a) Representative dot 
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plots of RAD23B versus pYSTAT3 expression in live cells. (b) Dot plots were used to 
quantify the percentage of total cells with different pYSTAT3-RAD23B staining 
combinations in live cells or (c) early-apoptotic cells. 10,000 events were collected in each 
experiment. (b-c) represents pooled data from two biological repeats plotted with SEM. 
Figure 4: RAD23B knockdown decreases HDACi-induced apoptosis and reduces the 
effect of FK228 on pYSTAT3. HUT-78 cells were treated with RAD23B siRNA and 
appropriate controls, for 48 hours as indicated. (a) RNA expression analysed by RT-PCR for 
RAD23B and the cyclophilin control. (b) Whole cell lysates were subject to immunoblot and 
were probed with antibodies to detect RAD23B and the β-Actin loading control. (c) 
Quantitative flow cytometry analysis of pYSTAT3 expression shown (left Y axis) and 
apoptosis (right Y axis) plotted with SD. (a-b: n = 1; c: pooled data from three biological 
repeats for which 10,000 events were collected). 
Figure 5: A distinct pattern of pYSTAT3 and RAD23B expression after FK228 
treatment in primary Sézary cells.  Peripheral blood CD4+ T-cells from two healthy 
volunteers (H1–2) and six SS patients (P3, P17–21) treated ex vivo with vehicle control or 1 
µM FK228 and stained with FVS, Annexin V-Pacific Blue, α-pYSTAT3-AF 647, α-STAT3-
PE and α-RAD23B-AF 488, prior to analysis by flow cytometry. ∆MFI in untreated and 
treated cells plotted with SEM for (a) STAT3 or (b) pYSTAT3. (c) Representative dot plot 
from Sézary cells from one patient showing RAD23B and pYSTAT3. (d-e) Percentage of (d) 
total live cells or (e) early-apoptotic cells in pooled Sézary cells was quantified, shown with 
SEM. (f) Percentage increase in early- and late-stage apoptosis relative to untreated cells.  
Figure 6: The STAT3 Y640F mutant persists in multiple tumour compartments over 
time and confers partial resistance to STAT3 transcriptional inhibition by FK228. (a) 
Sanger sequencing of PBMC DNA from serial blood samples (Blood I and II), lesional skin 
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and CD4+-enriched Sézary cell cDNA from Patient 17. (b) Dual luciferase reporter assays 
were conducted in HEK293T cells transfected to express a STAT3 Firefly luciferase reporter, 
the control Renilla reporter, WT or mutant STAT3 protein or the pCi empty vector. Bars 
represent Firefly/Renilla luminescence normalised to the empty vector, plotted with SEM; 
pooled data from three biological repeats each conducted in triplicate. Statistical significance 
was tested for the mutants relative to WT within each condition using a two-way ANOVA 
with multiple comparisons; *** p ≤ 0.001. 
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